patisiran (ONPATTRO) Report issue

Biologics Nucleic acid Orphan Drug FDA Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Patisiran, sold under the brand name Onpattro, is a medication used for the treatment of polyneuropathy in people with hereditary transthyretin-mediated amyloidosis, a fatal rare disease that is estimated to affect 50,000 people worldwide.   Wikipedia

More Chemistry
  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Drug Pricing (per unit)

United States

$1410.0460 - $1871.3560
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

aln-ttr02 | patisiran | patisiran sodium


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue